Tercica Finishes First With Increlex Orphan Approval; Insmed Left In Dust?

FDA will decide a battle for orphan drug exclusivity in the extreme short stature market between Tercica's Increlex and Insmed's SomatoKine if and when Insmed's agent is approved, Tercica predicted